Prostate cancer — all decisions

The Board remands the claims for service connection for prostate cancer and bladder cancer due to a duty to assist error, requiring further medical examination that considers all toxic exposure risk activities.

The Board denied an increased rating for prostate cancer and a compensable rating for myelodysplastic syndrome, but granted a separate rating for fatigue as a residual symptom of the service-connected myelodysplastic syndrome.

The Board denied the Veteran's petitions to readjudicate claims for service connection for bradycardia, diabetes mellitus, hypertension, emphysema, hypothyroidism, polypectomy, prostate cancer, and rheumatoid arthritis as new and relevant evidence was not received. The claim for an acquired psychiatric disability is remanded.

The Board granted an increased (Level 2) stipend in the PCAFC for the Veteran's caregiver due to the need for continuous supervision and protection based on the Veteran's medical conditions.

Service connection for prostate cancer on an accrued basis was granted based on the benefit-of-the-doubt doctrine, finding competent and credible evidence at least approximately balanced between service-connected prostatitis and prostate cancer. Service connection was denied for stomach cancer, colon cancer, skin cancer, the Veteran's cause of death, and dependency indemnity compensation benefits.

The appeal was dismissed due to the Veteran's passing during its pendency.

The Board granted service connection for prostate cancer as secondary to in-service exposure to diesel exhaust and erectile dysfunction as secondary to the now-service-connected prostate cancer.

The Board denied the appeals for increased ratings and TDIU, as the evidence did not support higher ratings or unemployability due to service-connected disabilities.

The Board denied the veteran's claim for an earlier effective date for service connection for prostate cancer, recurrent.

The Board denied service connection for obstructive sleep apnea, dismissed the appeal for a rating in excess of 40 percent for residuals of prostate cancer due to untimely filing, and dismissed the appeal for a compensable rating for erectile dysfunction.

The Board granted service connection for prostate cancer and remanded the claims for erectile dysfunction and voiding dysfunction as they may be related to the Veteran's service at Camp Lejeune.

The Board denied the Veteran's claims for service connection and compensation under § 1151 for prostate cancer status post prostatectomy, finding no evidence of in-service incurrence or a causal relationship to service.

The appeals for service connection and higher initial rating were dismissed due to concurrent election of review options.

The Board granted service connection for prostate cancer, hypertension, erectile dysfunction, and voiding dysfunction based on presumptive exposure to herbicide agents during the Veteran's service in Thailand.

The Board granted an earlier effective date of January 31, 2007, for the award of service connection for prostate cancer and SMC based on loss of use of a creative organ.

The Board remands the claims for service connection for prostate cancer and erectile dysfunction, to include as secondary to service-connected tuberculosis, for further development of the record.

The Board granted a 60 percent rating for prostate cancer with residuals, denied ratings in excess of 10 percent for tachycardia and an initial compensable rating for erectile dysfunction, and granted service connection for a psychiatric disability.

The Board granted an earlier effective date of August 10, 2022, for the grant of service connection for prostate cancer with residual urinary incontinence and erectile dysfunction under the PACT Act. The claims for an earlier effective date on a basis other than the PACT Act were remanded.

The Board granted service connection for prostate cancer and residuals, finding that the Veteran's condition was at least as likely as not caused by in-service exposure to contaminated water at Camp Lejeune.

The Board granted service connection for ischemic heart disease, prostate cancer, and bone cancer as due to herbicide exposure under the PACT Act. The claims for the heart disability and prostate cancer prior to August 10, 2022, were remanded.